Videos
RETURN TO DASHBOARD
Strong performance of The NGAL Test drives revenue growth
May 11, 2022
Meet the new management team
January 3, 2022
Opportunities according to the new management team
January 3, 2022
Key takeaways from the interim data analysis of our pivotal study of NGAL in pediatrics
September 2, 2021
Fantastic first half of the year driven by antibodies and The NGAL Test sales
August 24, 2021
BioPorto sees 'huge increase' in antibodies sales and 'good and steady' NGAL Test sales
Q1 2021 Report
May 12, 2021
2020 year-end financials and 2021’s anticipated milestones
An Edison interview with Peter Mørch Eriksen
March 19, 2021
BioPorto CEO explains why he expects 2021 to be a 'pivotal year'
March 18, 2021
BioPorto expects to submit De Novo FDA application for pediatric use of NGAL kidney test by summer
March 9, 2021
BioPorto maintains sales momentum of NGAL test, begins patient enrollment for coronavirus test
November 19, 2020
CEO Peter Mørck Eriksen og CFO Ole Larsen præsentere Q3 kvartalsregnkabet
November 19, 2020
BioPorto Diagnostics reveals progress on its co-developed 10-minute coronavirus test
September 18, 2020
BioPorto reveals another quarter of strong revenue from sales of its NGAL kidney damage test
August 25, 2020
BioPorto begins enrolling in its clinical study to treat children with severe acute kidney injury
June 25, 2020
BioPorto sees a 67% increase in NGAL-related revenue in its first quarter
May 11, 2020